Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Amevive NDA Filing For Psoriasis Expected In Second Half Of 2001

Executive Summary

Biogen plans to file an NDA for the T-cell modulator Amevive for psoriasis in the second half of 2001, VP-Medical Research Burt Adelman, MD, said during the company's first quarter conference call April 12.
Advertisement

Related Content

Genentech Considers Xanelim Chronic Psoriasis Therapy Indication
Genentech Considers Xanelim Chronic Psoriasis Therapy Indication
GlaxoSmithKline Is Mouthful But Still Hungry: Is Next Course Japanese?
GlaxoSmithKline Is Mouthful But Still Hungry: Is Next Course Japanese?
Advertisement
UsernamePublicRestriction

Register

PS037646

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel